Clinical Trial Update: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating palbociclib in combination with anastrozole for Stage 2-3 estrogen receptor-positive, HER2-negative breast cancer; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-06-02